In 2024, the healthcare sector spent $743.9 million on federal lobbying—$10 million less than 2023’s $745 million but maintaining its position as the largest lobbying sector in the United States for the 26th consecutive year. Pharmaceutical and health products companies led healthcare spending …
Pharmaceutical Research and Manufacturers of AmericaAmerican Medical AssociationAmerican Hospital AssociationPharmaceutical Care Management AssociationHealth insurance industry+1 morelobbyinghealthcarepharmaceutical-industrysystematic-corruptionregulatory-capture+1 more
President Obama signs the Patient Protection and Affordable Care Act into law, the most significant healthcare legislation since Medicare. While expanding coverage to millions of uninsured Americans, the law’s architecture reflects extensive industry lobbying, featuring an individual mandate …
Barack ObamaAmerica's Health Insurance PlansPharmaceutical Research and Manufacturers of AmericaMax BaucusLiz Fowler+1 morehealthcareinsurance-industryregulatory-captureindividual-mandatelobbying
President Clinton signs the FDA Modernization Act (FDAMA), codifying accelerated drug approval pathways developed during the AIDS crisis while expanding provisions favorable to pharmaceutical manufacturers including streamlined advertising approval. The law accelerates the transformation of FDA from …
Bill ClintonPharmaceutical Research and Manufacturers of AmericaFood and Drug Administration (FDA)James Jeffordshealthcarepharmaceutical-industryregulatory-capturefdadrug-safety
The Prescription Drug User Fee Act (PDUFA) of 1992 fundamentally restructured FDA drug approval financing by creating a direct financial relationship between pharmaceutical companies and regulators. The Act mandated drug companies pay fees to fund FDA drug reviews, which eventually comprised up to …
Food and Drug Administration (FDA)Pharmaceutical Research and Manufacturers of AmericaU.S. CongressPharmaceutical Companiesregulatory-capturepharmaceutical-industryfdagovernment-fundinginstitutional-transformation
President Reagan signs the Drug Price Competition and Patent Term Restoration Act, known as Hatch-Waxman, which ostensibly balances pharmaceutical innovation incentives with generic competition but creates loopholes that brand-name manufacturers exploit to extend monopoly pricing for decades. The …
Orrin HatchHenry WaxmanRonald ReaganPharmaceutical Research and Manufacturers of Americahealthcarepharmaceutical-industryregulatory-capturepatent-abuselobbying